Consolidation Therapy of Probiotics With Rifaximin Prevent Relapse in Rifaximin-Responsive Diarrhea-Predominant Irritable Bowel Syndrome: A Multicenter Randomized Clinical Trial.

J Gastroenterol HepatolAug 18, 2026 (epub)
Clinical ResearchGastroenterology

Jing Zhong, Zhengyang Xu, Wenwen Chen et al.

✦ AI-curated · Sources linked

In 30 seconds

This multicenter randomized clinical trial evaluated the effectiveness of consolidation therapy with Medilac-S probiotics following rifaximin treatment in patients with diarrhea-predominant irritable bowel syndrome (IBS-D). The study found that the relapse rate was significantly lower in the Medilac-S group compared to the control group (40.00% vs 58.33%, p = 0.0378), indicating improved long-term outcomes.

Key findings

  • The relapse rate was 40.00% in the Medilac-S group compared to 58.33% in the control group (p = 0.0378).
  • Medilac-S therapy resulted in a significant reduction in bowel movement frequency (1.73 ± 0.75 vs. 2.53 ± 1.20, p < 0.001).
  • Stool consistency improved significantly in the Medilac-S group (BSFS 4.38 ± 1.06 vs. 5.15 ± 0.95, p < 0.001).

Why it matters

The study highlights the potential of probiotics as a consolidation therapy to prevent relapse in IBS-D patients after rifaximin treatment, addressing a significant gap in current management strategies.

Source

PubMed · PMID 42609157

Published in J Gastroenterol Hepatol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.